Stock Track | BeiGene Plunges 8% Amid Hong Kong Market Rout on Stimulus Uncertainty

Stock Track10-14

Shares of BeiGene, a leading biopharmaceutical company based in Beijing, tumbled nearly 8.5% on Monday, mirroring the broader market selloff in Hong Kong amid growing uncertainty over the scale and timing of further economic stimulus measures from Chinese authorities.

The Hang Seng Index, Hong Kong's benchmark, fell 0.75% as investors were left disappointed after China's finance minister, Lan Foan, hinted at significantly increasing debt but failed to provide specific details on the size of the stimulus package during a press conference over the weekend.

BeiGene, along with other pharmaceutical giants like Innovent Biologics and CSPC Pharmaceutical, bore the brunt of the selloff, with their shares plunging around 5% at the close. Investor sentiment was further dampened by data released on Sunday showing a deceleration in consumer inflation and a prolonged decline in producer prices, fueling concerns over the health of the Chinese economy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment